Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by PharmaEssentia USA Corporation

News headline image
PharmaEssentia to Present Additional BESREMi® Data Across Polycythemia Vera and Essential Thrombocythemia at ASH 2026
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
FDA Approves PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) for Adults with Essential Thrombocythemia, A Rare Blood Cancer
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Taiwan Approval of BESREMi® for Essential Thrombocythemia, Marking First Global Approval in ET
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET)
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
FDA Confirms a PDUFA Goal Date of August 30, 2026 for the sBLA Submission of Ropeginterferon Alfa-2b-njft in Essential Thrombocythemia (ET)
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Positive Topline Phase 2b Data from EXCEED-ET Study Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia USA Announces Appointment of Jeffrey Williams as Independent Director
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Presentation at J.P. Morgan Healthcare Conference and Strategic Priorities for 2026
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Publication of Phase 3 SURPASS-ET Results in The Lancet Haematology
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Presentations at ASH 2025
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Participate at Morgan Stanley 23rd Annual Global Healthcare Conference
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Announces Presentations at EHA 2025 Highlighting Clinical Advances in Myeloproliferative Neoplasms
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia to Present Phase 3 SURPASS-ET Data in Oral Session at 2025 ASCO Annual Meeting
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Highlights Availability of BESREMi® (ropeginterferon alfa-2b-njft) for Patients Affected by Pegasys® (peginterferon alfa-2a) Drug Shortage
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
BESREMi® (Ropeginterferon alfa-2B) Shows Greatest Benefit Among Cytoreductive Therapies in Lowering Symptomatic Burden of Polycythemia Vera (PV): Real-World Analysis Published at ASCO
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
CORRECTING and REPLACING PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia and MPN Advocacy & Education International Launch New Educational Initiative to Empower People Living With Polycythemia Vera (PV)
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi® (ropeginterferon alfa-2b-njft) as a Preferred Intervention for Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
New Ropeginterferon alfa-2b Data Show Importance of Proactive Care Earlier in the Polycythemia Vera Patient Journey
From PharmaEssentia USA Corporation
Via Business Wire
News headline image
Presentations on Ropeginterferon Alfa-2b During ASH Annual Meeting Highlight Momentum in the Care of Polycythemia Vera
From PharmaEssentia USA Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.